Collaborative Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Information related to collaborative arrangements
Less: amortization of capitalized fees paid to a related party	$ (3,455)	$ (3,233)	$ (10,367)	$ (7,611)
Royalty revenue	13,341	729	30,449	342
Revenue from Collaborative Arrangements	221	270	664	811
Total revenue	13,562	999	$ 31,113	1,153
Theravance Biopharma | Common Stock
Information related to collaborative arrangements
Number of ordinary shares sold			436,802
GSK
Information related to collaborative arrangements
Royalties from a related party	16,796	3,962	$ 40,816	7,953
Less: amortization of capitalized fees paid to a related party	(3,455)	(3,233)	(10,367)	(7,611)
Royalty revenue	13,341	729	30,449	342
Total revenue	13,562	999	31,113	1,153
GSK | MABA
Information related to collaborative arrangements
Potential future contingent payments receivable	363,000		363,000
Long-acting beta agonist (LABA) collaboration | GSK
Information related to collaborative arrangements
Less: amortization of capitalized fees paid to a related party	(3,500)	(3,200)	$ (10,400)	(7,600)
Obligation for milestone payments					$ 220,000
Royalty rate for first level of annual global net sales (as a percent)			15.00%
Annual global sales level used to determine royalty rate			$ 3,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)			5.00%
Long-acting beta agonist (LABA) collaboration | GSK | Minimum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)			6.50%
Long-acting beta agonist (LABA) collaboration | GSK | Maximum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)			10.00%
2004 Strategic alliance | GSK | MABA
Information related to collaborative arrangements
Revenue from Collaborative Arrangements	$ 221	$ 270	$ 664	$ 811